Evidence for a tetrahydrobiopterin deficit in schizophrenia

Neuropsychobiology

Volumn 52, Issue 4, 2005, Pages 190-201

  Richardson, M A ^a,b   Read, Laura L ^a,b   Taylor Clelland, Catherine L ^a,c   Reilly, Margaret A ^a   Chao, Helen M ^a,b   Guynn, Robert W ^f   Suckow, Raymond F ^d,e   Clelland, James D ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e Houston Medical School ^*  (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Amine neurotransmitters; Biopterin; Glutamate; GTP cyclohydrolase I feedback regulatory gene; GTP cyclohydrolase I feedback regulatory protein; Phenylalanine; Schizophrenia; Tetrahydrobiopterin; Variant sequence

Indexed keywords

BIOPTERIN; DOPAMINE; GLUTAMIC ACID; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; NEUROLEPTIC AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PHENYLALANINE; SEROTONIN; TETRAHYDROBIOPTERIN;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNOLOGY; FEEDBACK SYSTEM; FEMALE; GENE MUTATION; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DIET; REGULATOR GENE; SCHIZOPHRENIA; SEQUENCE ANALYSIS;

ADULT; BIOPTERIN; DEMOGRAPHY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; GTP CYCLOHYDROLASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NITRIC OXIDE; PHENYLALANINE; PROTEINS; SCHIZOPHRENIA; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 27944462585     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089002     Document Type: Article

References (93)

1. Blau N, Thony B, Cotton RGH, Hyland K: Disorders of tetrahydrobiopterin and related biogenic amines; in Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2001, pp 1725-1776.
2. Kaufman S: Tetrahydrobiopterin. Basic Biochemistry and Role in Human Disease. Baltimore, Johns Hopkins University Press, 1997.
3. Snyder SH, Ferris CD: Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 2000;157:1738-1751.
4. Kiss JP: Role of nitric oxide in the regulation of monoaminergic neurotransmission. Brain Res Bull 2000;52:459-466.
5. Prast H, Philippu A: Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001;64:51-68.
6. Schuman EM, Madison DV: Nitric oxide and synaptic function. Annu Rev Neurosci 1994;17:153-183.
7. Segieth J, Getting SJ, Biggs CS, Whitton PS: Nitric oxide regulates excitatory amino acid release in a biphasic manner in freely moving rats. Neurosci Lett 1995;200:101-104.
8. Kamisaki Y, Maeda K, Ishimura M, Omura H, Moriwaki Y, Itoh T: No enhancement by nitric oxide of glutamate release from P2 and P3 synaptosomes of rat hippocampus. Brain Res 1994;644:128-134.
9. Koshimura K, Miwa S, Lee K, Fujiwara M, Watanabe Y: Enhancement of dopamine release in vivo from the rat striatum by dialytic perfusion of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin. J Neurochem 1990;54:1391-1397.
10. Mataga N, Imamura K, Watanabe Y: 6R-Tetrahydrobiopterin perfusion enhances dopamine, serotonin, and glutamate outputs in dialysate from rat striatum and frontal cortex. Brain Res 1991;551:64-71.
11. Koshimura K, Miwa S, Watanabe Y: Dopamine-releasing action of 6R-L-erythro-tetrahydrobiopterin: analysis of its action site using sepiapterin. J Neurochem 1994;63:649-654.
12. Watanabe Y, Mataga N, Imamura K, Onoe H, Koshimura K, Miwa S, Hartvig P, Tedroff J, Bjurling P, Langstrom B: Tetrahydrobiopterin and dopamine release. Jpn J Psychiatry Neurol 1991;45:513-514.
13. Koshimura K, Ohue T, Watanabe Y, Miwa S: 6R-L-Erythro-5,6,7,8- tetrahydrobiopterin: a regulator of neurotransmitter release. Adv Exp Med Biol 1993;338:313-319.
14. Miwa S, Koshimura K: 6R-L-Erythro-5,6,7,8-tetrahydrobiopterin and dopamine release. Pteridines 1995;6:173-180.
15. Sumi-Ichinose C, Urano F, Kuroda R, Ohye T, Kojima M, Tazawa M, Shiraishi H, Hagino Y, Nagatsu T, Nomura T, Ichinose H: Catecholamines and serotonin are differently regulated by tetrahydrobiopterin: a study from 6- pyruvoyltetrahydropterin synthase knockout mice. J Biol Chem 2001;276:41150-41160.
16. Milstien S, Jaffe H, Kowlessur D, Bonner TI: Purification and cloning of the GTP cyclohydrolase I feedback regulatory protein, GFRP. J Biol Chem 1996;271:19743-19751.
17. Harada T, Kagamiyama H, Hatakeyama K: Feedback regulation mechanisms for the control of GTP cyclohydrolase I activity. Science 1993;260:1507-1510.
18. Ponzone A, Guardamagna O, Spada M, Ponzone R, Sartore M, Kierat L, Heizmann CW, Blau N: Hyperphenylalaninemia and pterin metabolism in serum and erythrocytes. Clin Chim Acta 1993;216:63-71.
19. Leeming RJ, Hall SK, Surplice IM, Green A: Relationship between plasma and red cell biopterins in acute and chronic hyperphenylalaninaemia. J Inherit Metab Dis 1990;13:883-887.
20. Leeming RJ, Blair JA, Green A, Raine DN: Biopterin derivatives in normal and phenylketonuric patients after oral loads of L-phenylalanine, L-tyrosine, and L-tryptophan. Arch Dis Child 1976;51:771-777.
21. Joyce JN: The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology 1993;112:S16-S34.
22. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE: Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 1998;44:1099-1117.
23. Van Kammen DP, Kelley M: Dopamine and norepinephrine activity in schizophrenia. An integrative perspective. Schizophr Res 1991;4:173-191.
24. Xing G, Chavko M, Zhang LX, Yang S, Post RM: Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 2002;58:21-30.
25. Shinkai T, Ohmori O, Hori H, Nakamura J: Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol Psychiatry 2002;7:560-563.
26. Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH: Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 2000;157:1811-1823.
27. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE Jr, Jones EG: Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30.
28. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-1377.
29. Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT: Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry 1998;44:667-674.
30. Department of Health and Human Services: Protection of Human Subjects. The Common Rule. In OPRR Reports. Washington, Department of Health and Human Services, 1991.
31. Department of Health Education and Welfare: Protection of Human Subjects: Belmont Report; Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. In Federal Register. Washington, 1979, vol 44, p 23192.
32. Fukushima T, Nixon JC: Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem 1980;102:176-188.
33. Fiege B, Ballhausen D, Kierat L, Leimbacher W, Goriounov D, Schircks B, Thony B, Blau N: Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet Metab 2004;81:45-51.
34. Kay AD, Milstien S, Kaufman S, Creasey H, Haxby JV, Cutler NR, Rapoport SI: Cerebrospinal fluid biopterin is decreased in Alzheimer's disease. Arch Neurol 1986;43:996-999.
35. Hariharan M, Naga S, VanNoord T: Systematic approach to the development of plasma amino acid analysis by high-performance liquid chromatography with ultraviolet detection with precolumn derivatization using phenyl isothiocyanate. J Chromatogr 1993;621:15-22.
36. Richardson MA, Read LL, Clelland JD, Chao HM, Reilly MA, Romstad A, Suckow RF: Phenylalanine hydroxylase gene in psychiatric patients: screening and functional assay of mutations. Biol Psychiatry 2003;53:543-553.
37. Tabachnick BG, Fidell LS: Using Multivariate Statistics. New York, Harper and Row, 1983.
38. SPSS: SPSS for Windows, Rel 11.5.0.2002. Chicago, SPSS Inc, 2002.
39. Vandenbroucke I, Callens T, De Paepe A, Messiaen L: Complex splicing pattern generates great diversity in human NF1 transcripts. BMC Genomics 2002;3:13.
40. Harris NL, Senapathy P: Distribution and consensus of branch point signals in eukaryotic genes: a computerized statistical analysis. Nucleic Acids Res 1990;18:3015-3019.
41. Leeming RJ, Blair JA, Melikian V, O'Gorman DJ: Biopterin derivatives in human body fluids and tissues. J Clin Pathol 1976;29:444-451.
42. Hossain MA, Masserano JM, Weiner N: Comparative effects of electroconvulsive shock and haloperidol on in vivo tyrosine hydroxylation and tetrahydrobiopterin in the brain of rats with 6-hydroxydopamine lesions. Brain Res 1992;598:121-126.
43. Lohr JB, Flynn K: Smoking and schizophrenia. Schizophr Res 1992;8:93-102.
44. Bozikas VP, Niopas I, Kafantari A, Kanaze FI, Gabrieli C, Melissidis P, Gamvrula K, Fokas K, Karavatos A: No increased levels of the nicotine metabolite cotinine in smokers with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1-6.
45. Serova L, Sabban EL: Involvement of alpha 7 nicotinic acetylcholine receptors in gene expression of dopamine biosynthetic enzymes in rat brain. J Pharmacol Exp Ther 2002;303:896-903.
46. Tsai MJ, Lee EH: Nicotine enhances brain biopterin concentration in rats. Neurochem Int 1995;27:213-217.
47. Tsai MJ, Wang HL, Lee EH: Interactive effects of nicotine and MPTP on striatal tetrahydrobiopterin in mice. J Biomed Sci 1996;3:47-53.
48. Kapatos G, Kaufman S: Peripherally administered reduced pterins do enter the brain. Science 1981;212:955-956.
49. Yamaguchi T, Nagatsu T, Sugimoto T, Matsuura S, Kondo T, Iizuka R, Narabayashi H: Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson's disease. Science 1983;219:75-77.
50. Nagatsu T, Yamaguchi T, Rahman MK, Trocewicz J, Oka K, Hirata Y, Nagatsu I, Narabayashi H, Kondo T, Iizuka R: Catecholamine-related enzymes and the biopterin cofactor in Parkinson's disease and related extrapyramidal diseases. Adv Neurol 1984;40:467-473.
51. Kaufman S, Kapatos G, McInnes RR, Schulman JD, Rizzo WB: Use of tetrahydropterins in the treatment of hyperphenylalaninemia due to defective synthesis of tetrahydrobiopterin: evidence that peripherally administered tetrahydropterins enter the brain. Pediatrics 1982;70:376-380.
52. Blau N, Dhondt JL: BIODEF: international database of tetrahydrobiopterin deficiencies. http://www.bh4.org. 2004.
53. Kirch DG, Alexander RC, Suddath RL, Papadopoulos NM, Kaufmann CA, Daniel DG, Wyatt RJ: Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J Neural Transm Gen Sect 1992;89:219-232.
54. Bauer K, Kornhuber J: Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur Arch Psychiatry Neurol Sci 1987;236:257-259.
55. LeWitt PA, Miller LP, Levine RA, Lovenberg W, Newman RP, Papavasiliou A, Rayes A, Eldridge R, Burns RS: Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials. Neurology 1986;36:760-764.
56. Blau N, Bonafe L, Thony B: Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. Mol Genet Metab 2001;74:172-185.
57. Leuzzi V, Carducci C, Carducci C, Cardona F, Artiola C, Antonozzi I: Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology 2002;59:1241-1243.
58. Hahn H, Trant MR, Brownstein MJ, Harper RA, Milstien S, Butler IJ: Neurologic and psychiatric manifestations in a family with a mutation in exon 2 of the guanosine triphosphate-cyclohydrolase gene. Arch Neurol 2001;58:749-755.
59. Sawa A, Snyder SH: Schizophrenia: diverse approaches to a complex disease. Science 2002;296:692-695.
60. Bray NJ, Owen MJ: Searching for schizophrenia genes. Trends Mol Med 2001;7:169-174.
61. Kapatos G, Hirayama K, Shimoji M, Milstien S: GTP cyclohydrolase I feedback regulatory protein is expressed in serotonin neurons and regulates tetrahydrobiopterin biosynthesis. J Neurochem 1999;72:669-675.
62. Blau N, Bonafe L, Krageloh-Mann I, Thony B, Kierat L, Hausler M, Ramaekers V: Cerebrospinal fluid pterins and folates in Aicardi-Goutières syndrome: a new phenotype. Neurology 2003;61:642-647.
63. Goux-Pelletan M, Libri D, d'Aubenton-Carafa Y, Fiszman M, Brody E, Marie J: In vitro splicing of mutually exclusive exons from the chicken beta-tropomyosin gene: role of the branch point location and very long pyrimidine stretch. EMBO J 1990;9:241-249.
64. Libri D, Balvay L, Fiszman MY: In vivo splicing of the beta tropomyosin pre-mRNA: a role for branch point and donor site competition. Mol Cell Biol 1992;12:3204-3215.
65. Chavanas S, Gache Y, Vailly J, Kanitakis J, Pulkkinen L, Uitto J, Ortonne J, Meneguzzi G: Splicing modulation of integrin beta4 pre-mRNA carrying a branch point mutation underlies epidermolysis bullosa with pyloric atresia undergoing spontaneous amelioration with ageing. Hum Mol Genet 1999;8:2097-2105.
66. Li M, Pritchard PH: Characterization of the effects of mutations in the putative branch-point sequence of intron 4 on the splicing within the human lecithin:cholesterol acyltransferase gene. J Biol Chem 2000;275:18079-18084.
67. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG: Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993;3:151-156.
68. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel F-A: Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 1985;147:276-282.
69. Lindstrom LH: Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Res 1985;14:265-273.
70. Tuckwell HC, Koziol JA: A meta-analysis of homovanillic acid concentrations in schizophrenia. Int J Neurosci 1993;73:109-114.
71. Wieselgren IM, Lindstrom LH: CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Res 1998;81:101-110.
72. Lindstrom LH, Wieselgren IM, Klockhoff I, Svedberg A: Relationship between abnormal brainstem auditory-evoked potentials and subnormal CSF levels of HVA and 5-HIAA in first-episode schizophrenic patients. Biol Psychiatry 1990;28:435-442.
73. Potkin SG, Weinberger DR, Linnoila M, Wyatt RJ: Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. Am J Psychiatry 1983;140:21-25.
74. Sedvall G, Iselius L, Nyback H, Oreland L, Oxenstierna G, Ross SB, Wiesel F-A: Genetic studies of CSF monoamine metabolites; in Usdin E, Asberg M, Bertilsson L, Sjoqvist F (eds): Frontiers in Biochemical and Pharmacological Research in Depression. Advances in Biochemical Psychopharmacology. New York, Raven Press. 1984, vol 39, pp 79-85.
75. Sedvall GC, Wode-Helgodt B: Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients. Arch Gen Psychiatry 1980;37:1113-1116.
76. Miwa S, Watanabe Y, Koshimura K, Masaki T: A novel function of tetrahydrobiopterin. Nippon Yakurigaku Zasshi 1992;100:367-381.
77. Kosenko E, Llansola M, Montoliu C, Monfort P, Rodrigo R, Hernandez-Viadel M, Erceg S, Sanchez-Perez AM, Felipo V: Glutamine synthetase activity and glutamine content in brain: modulation by NMDA receptors and nitric oxide. Neurochem Int 2003;43:493-499.
78. Oja SS, Saransaari P: Modulation of taurine release by glutamate receptors and nitric oxide. Prog Neurobiol 2000;62:407-425.
79. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT: Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-836.
80. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA: Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 2000;157:1141-1149.
81. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML: Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001;41:237-260.
82. Dal Bo G, St-Gelais F, Danik M, Williams S, Cotton M, Trudeau LE: Dopamine neurons in culture express VGLUT2 explaining their capacity to release glutamate at synapses in addition to dopamine. J Neurochem 2004;88:1398-1405.
83. Stornetta RL, Sevigny CP, Guyenet PG: Vesicular glutamate transporter DNPI/VGLUT2 mRNA is present in C1 and several other groups of brainstem catecholaminergic neurons. J Comp Neurol 2002;444:191-206.
84. Fremeau RT Jr, Burman J, Qureshi T, Tran CH, Proctor J, Johnson J, Zhang H, Sulzer D, Copenhagen DR, Storm-Mathisen J, Reimer RJ, Chaudhry FA, Edwards RH: The identification of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate. Proc Natl Acad Sci USA 2002;99:14488-14493.
85. Gras C, Herzog E, Bellenchi GC, Bernard V, Ravassard P, Pohl M, Gasnier B, Giros B, El Mestikawy S: A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons. J Neurosci 2002;22:5442-5451.
86. Stornetta RL, Sevigny CP, Schreihofer AM, Rosin DL, Guyenet PG: Vesicular glutamate transporter DNPI/VGLUT2 is expressed by both C1 adrenergic and nonaminergic presympathetic vasomotor neurons of the rat medulla. J Comp Neurol 2002;444:207-220.
87. West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA: Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann NY Acad Sci 2003;1003:53-74.
88. Sesack SR, Carr DB, Omelchenko N, Pinto A: Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann NY Acad Sci 2003;1003:36-52.
89. Laruelle M, Kegeles LS, Abi-Dargham A: Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci 2003;1003:138-158.
90. 1 receptor function by physical interaction with the NMDA receptors. J Neurosci 2004;24:1149-1158.
91. Blau N, Thony B, Spada M, Ponzone A: Tetrahydrobiopterin and inherited hyperphenylalaninemias. Turk J Pediatr 1996;38:19-35.
92. Thony B, Auerbach G, Blau N: Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 2000;347:1-16.
93. Bonafe L, Thony B, Leimbacher W, Kierat L, Blau N: Diagnosis of dopa-responsive dystonia and other tetrahydrobiotperin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem 2001;47:477-485.